Sign in to fuzzto save your conversations, follow your research and come back anytime.
India Glycols
INDIAGLYCO
NSE
BSE
NSEBSESectorConsumer Goods
248.00
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
India Glycols posts stronger revenue and profit growth while cutting finance costs, though share dilution and lower trading liquidity weigh on per-share returns.
Finance cost falls from ₹45 Cr to ₹25 Cr from Q1 FY26 to Q1 FY27 — lower interest burden improves cash flow
Average daily trading value drops from ₹36.57 Cr to ₹12.71 Cr from Q1 FY26 to Q1 FY27 — reduced market liquidity
Profit after tax climbs from ₹65 Cr to ₹97 Cr from Q2 FY26 to Q1 FY27 — stronger bottom-line growth
Foreign institutional ownership falls from 3.44% to 2.24% from Q1 FY26 to Q1 FY27 — sustained foreign investor exit
Gross revenue surges from ₹2,503 Cr to ₹2,988 Cr from Q1 FY26 to Q1 FY27 — expanding top-line sales
Potable Spirits revenue share shrinks from 33% to 7% from Q1 FY26 to Q1 FY27 — declining sales contribution
Ennature Biopharma EBIT rises from ₹1 Cr to ₹27 Cr from Q1 FY26 to Q1 FY27 — rapid segment scaling
Earnings per share decline from ₹17.1 to ₹11.4 from Q1 FY26 to Q1 FY27 — diluted per-share returns
Domestic institutional holding grows from 1.39% to 5.22% from Q1 FY26 to Q1 FY27 — steady local investor confidence
Total shares outstanding double from 3.10 to 6.70 from Q1 FY26 to Q1 FY27 — increased equity dilution
